Product
Marizomib
Name
Marizomib
3 clinical trials
1 drug
11 indications
Indication
Diffuse Intrinsic Pontine GliomaIndication
Pediatric Brainstem GliomaIndication
Pediatric Brainstem GliosarcomaIndication
RecurrentIndication
Pediatric CancerIndication
Pediatric Brain TumorIndication
GliomaIndication
GlioblastomaIndication
Multiple MyelomaIndication
Multiple Myeloma in RelapseIndication
RefractoryDrug
MarizomibClinical trial
Phase 1 Trial of Marizomib Alone and in Combination With Panobinostat for Children With Diffuse Intrinsic Pontine GliomaStatus: Terminated, Estimated PCD: 2024-02-14
Clinical trial
A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed GlioblastomaStatus: Completed, Estimated PCD: 2022-08-23
Clinical trial
A Phase 2 Study With Safety Run-In of Marizomib, Pomalidomide, and Dexamethasone For Relapsed and Refractory Multiple Myeloma and CNS MyelomaStatus: Not yet recruiting, Estimated PCD: 2025-12-02